Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8933 USD | +10.82% | +21.87% | +10.28% |
25/04 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
25/04 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Equities
- HOOK Stock
- Revisions HOOKIPA Pharma Inc.